 |
|
| Systematic (IUPAC) name | |
|---|---|
| 5-allyl-5-sec-butylpyrimidine-2,4,6(1H,3H,5H)-trione | |
| Identifiers | |
| CAS number | 115-44-6 |
| ATC code | N05CA07 |
| PubChem | 8275 |
| Chemical data | |
| Formula | C11H16N2O3 |
| Mol. mass | 224.256 g/mol |
| Synonyms | 5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
 (what is this?) (verify) |
|
Talbutal (Lotusate), also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. It is a structural isomer of butalbital.
Description:
Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Pharmacology:
Talbutal is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Mechanism of Action:
Talbutal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Toxicity:
Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension, and shock.
|
|||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
